Payment overview · 2025
General Payments
$168.70
5 reported records · 5 companies
Healthcare provider profile · identity verified
Alexandra Capellan, M.D.
Allopathic & Osteopathic Physicians|General Practice · PONCE, PR · NPI 1952584849
Verified facts
What the public records show
CMS Open Payments records show Alexandra Capellan, M.D. received $168.70 in general payments during 2025 across 5 reported records.
GlaxoSmithKline, LLC. accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 503 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.30 | 30.4% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $43.16 | 25.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.71 | 17.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.27 | 15.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.26 | 11.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $168.70 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.71 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $25.27 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
503 | 69 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 625 | 97 |
| Famotidine | Famotidine | 603 | 107 |
| Synthroid | Levothyroxine Sodium | 503 | 69 |
| Gabapentin | Gabapentin | 412 | 72 |
| Losartan Potassium | Losartan Potassium | 408 | 66 |
| Lisinopril | Lisinopril | 345 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 312 | 71 |
| Metformin Hcl | Metformin Hcl | 280 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 40 |
| Simvastatin | Simvastatin | 237 | 40 |
| Omeprazole | Omeprazole | 225 | 40 |
| Montelukast Sodium | Montelukast Sodium | 205 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 174 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 163 | 28 |
| Glipizide | Glipizide | 162 | 22 |
| Carvedilol | Carvedilol | 161 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 27 |
| Furosemide | Furosemide | 149 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 29 |
| Glimepiride | Glimepiride | 138 | 19 |
| Alendronate Sodium | Alendronate Sodium | 116 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 19 |
| Meloxicam | Meloxicam | 108 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 17 |
| Eliquis | Apixaban | 96 | 15 |
| Fenofibrate | Fenofibrate | 96 | 20 |
| Clonazepam | Clonazepam | 94 | 21 |
| Pregabalin | Pregabalin | 91 | 20 |
| Ezetimibe | Ezetimibe | 90 | 14 |
| Jentadueto | Linagliptin/Metformin Hcl | 85 | 16 |
| Enalapril Maleate | Enalapril Maleate | 84 | 16 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 83 | suppressed |
| Jardiance | Empagliflozin | 83 | 13 |
| Allopurinol | Allopurinol | 82 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 17 |
| Indapamide | Indapamide | 75 | 11 |
| Nabumetone | Nabumetone | 73 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 13 |
| Temazepam | Temazepam | 71 | 11 |
| Alprazolam | Alprazolam | 69 | 11 |
| Spironolactone | Spironolactone | 69 | suppressed |
| Memantine Hcl | Memantine Hcl | 67 | 11 |
| Atenolol | Atenolol | 66 | suppressed |
| Latanoprost | Latanoprost | 64 | suppressed |
| Azithromycin | Azithromycin | 61 | 48 |
| Donepezil Hcl | Donepezil Hcl | 60 | 12 |
| Levetiracetam | Levetiracetam | 60 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 59 | 12 |
| Farxiga | Dapagliflozin Propanediol | 58 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 54 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 54 | suppressed |
| Naproxen | Naproxen | 51 | 15 |
| Finasteride | Finasteride | 50 | suppressed |
| Risperidone | Risperidone | 50 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 48 | 26 |
| Diltiazem Hcl | Diltiazem Hcl | 47 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 40 | suppressed |
| Gemfibrozil | Gemfibrozil | 40 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 30 |
| Irbesartan | Irbesartan | 36 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 35 | suppressed |
| Methotrexate | Methotrexate Sodium | 34 | suppressed |
| Prednisone | Prednisone | 34 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Methylprednisolone | Methylprednisolone | 33 | 26 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 22 |
| Sertraline Hcl | Sertraline Hcl | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 20 |
| Meclizine Hcl | Meclizine Hcl | 30 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 28 | 19 |
| Trueplus Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 28 | suppressed |
| Cilostazol | Cilostazol | 27 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 25 | 15 |
| Tradjenta | Linagliptin | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Insulin Lispro | Insulin Lispro | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Ssd | Silver Sulfadiazine | 22 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 18 |
| Dilantin | Phenytoin Sodium Extended | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Etodolac | Etodolac | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Mupirocin | Mupirocin | 18 | 11 |
| Baclofen | Baclofen | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 17 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Sure Comfort | Syring-Needl,disp,insul,0.3 Ml | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Vimpat | Lacosamide | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Invokamet | Canagliflozin/Metformin Hcl | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Tacrolimus | Tacrolimus | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Hadlima(Cf) Pushtouch | Adalimumab-Bwwd | 11 | suppressed |
| Levoxyl | Levothyroxine Sodium | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $168.70 · 5 records | GlaxoSmithKline, LLC. | AIRSUPRA, ELIQUIS, SKYRIZI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error